Q2 2024 Earnings Summary
- Strengthening Growth in China: Organon expects a return to mid-single-digit growth in China in the second half of 2024 and anticipates more robust growth in 2025 and beyond, as they pass through the Volume-Based Procurement (VBP) impact. 80% of their Established Brands business will have gone through VBP by the end of this year, setting the stage for solid growth momentum. ,
- Strong Performance and Future Potential of Hadlima: Hadlima, their HUMIRA biosimilar, is experiencing significant growth, with total prescriptions (TRx) up 60% quarter over quarter. Organon expects to be among the top two or three biosimilars for HUMIRA. Their strategy of offering a high-quality product at the lowest net cost is paying off, and they are confident in ongoing performance, especially as they anticipate gaining interchangeability status next year. ,
- NEXPLANON's Extended Market Protection and Growth Prospects: The NEXPLANON 5-year efficacy study met its primary endpoint, and Organon is preparing for regulatory submission. The extension to a 5-year indication and existing device patents until 2030 provide data exclusivity and protection from generic competition. This positions NEXPLANON for continued robust growth until the end of the decade and possibly beyond. ,
- Organon faces increased competition in the biosimilars market, particularly with Teva's recent significant contract wins and the approval of interchangeability for its biosimilar HUMIRA product, which could impact Organon's Hadlima volumes and market share.
- There is limited visibility on Organon's R&D pipeline and a cautious approach to R&D spending, which may constrain future growth prospects and limit the company's ability to offset pressures from upcoming loss of exclusivity events.
- Operating margins may remain flat or have limited growth in the near term due to cost pressures from mandatory price revisions in markets like Japan and Europe, as well as the impact of upcoming LOEs, suggesting potential challenges in improving profitability.
-
Operating Margin Outlook
Q: Will margins improve in 2024 and 2025?
A: Management expects operating margins to remain fairly stable through the rest of 2024. While it's too soon to provide guidance for 2025, they believe holding margins is realistic for 2025, even with modest LOE exposure hitting in 2025. Beyond 2025, they anticipate improving gross margins as they separate the manufacturing network from Merck, benefiting from substantial opportunities and a better product mix toward growth products introduced since the spin-off. -
Hadlima Growth Strategy
Q: How will you drive Hadlima volumes amid competition?
A: Organon's strategy for Hadlima focuses on providing a high-quality, frictionless experience comparable to HUMIRA at the lowest net cost to maximize patient access. About 45% of the market is in the low net cost segment where they're gaining growth. They project to be among the top 2 or 3 biosimilars for HUMIRA, with TRx growing about 60% quarter over quarter. Interchangeability on high concentration hasn't significantly impacted their growth, and they expect to secure interchangeability designation when exclusivity expires next May. -
China Sales Outlook
Q: What is the outlook for China sales amid challenges?
A: Management anticipates mid-single-digit growth in China in the second half of the year. Despite past impacts from anticorruption campaigns and VBP rounds, they have washed through these issues and expect more robust growth in 2025 and beyond after passing through the VBP challenges. They don't foresee a continuation of downdrafts and believe they're in good shape for the year. -
R&D Spend and Pipeline
Q: How are you balancing R&D spend and margins?
A: Organon is excited about their pipeline, particularly asset 6219 for endometriosis, with Phase IIa/IIb data expected next year. They are being prudent with capital, focusing on tuck-in deals like the one with Lilly, which has been very profitable in the first few months. They prioritize balancing pipeline investment with margin stability, being judicious with R&D expenditures. -
NEXPLANON 5-Year Indication
Q: What's the plan for NEXPLANON's 5-year data and pricing?
A: The 5-year efficacy indication for NEXPLANON is the same product, now demonstrating efficacy for five years. Organon is preparing for submission to the FDA and is considering pricing options. This extension strengthens their market position, with exclusivity of their unique inserter device until 2030, ensuring robust presence until the end of the decade and beyond. -
Future EBITDA and Cost Structure
Q: Can you maintain or reduce cost structure beyond 2024?
A: Management believes that holding margins is realistic for 2025, even with upcoming LOE impacts. They foresee opportunities to improve gross margins after 2025 by separating the manufacturing network from Merck and benefiting from a better product mix focused on growth products from business development efforts. The current cost structure is largely right-sized, allowing for operating leverage.
Research analysts covering Organon &.